

# World Journal of *Hepatology*

*World J Hepatol* 2022 June 27; 14(6): 1053-1268



### REVIEW

- 1053** Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection  
*Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA*

### MINIREVIEWS

- 1074** Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?  
*Rajappa S, Rau KM, Dattatreya PS, Ramaswamy A, Fernandes P, Pruthi A, Cheng R, Lukanowski M, Huang YH*
- 1087** Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions  
*Lanzaro F, Guarino S, D'Addio E, Salvatori A, D'Anna JA, Marzuillo P, Miraglia del Giudice E, Di Sessa A*
- 1099** Liver dysfunction during COVID-19 pandemic: Contributing role of associated factors in disease progression and severity  
*Sahu T, Pande B, PL M, Verma HK*
- 1111** Understanding fatigue in primary biliary cholangitis: From pathophysiology to treatment perspectives  
*Lynch EN, Campani C, Innocenti T, Dragoni G, Biagini MR, Forte P, Galli A*
- 1120** Fibrosis regression following hepatitis C antiviral therapy  
*Elsharkawy A, Samir R, El-Kassas M*

### ORIGINAL ARTICLE

#### Basic Study

- 1131** COVID-19 liver and gastroenterology findings: An *in silico* analysis of SARS-CoV-2 interactions with liver molecules  
*Peiter GC, de Souza CBT, de Oliveira LM, Pagliarin LG, dos Anjos VNF, da Silva FAF, de Melo FF, Teixeira KN*

#### Case Control Study

- 1142** Clinical outcomes of coronavirus disease 2019 in liver transplant recipients  
*Shafiq M, Gibson C*

#### Retrospective Cohort Study

- 1150** Intensive care unit readmission in adult Egyptian patients undergoing living donor liver transplant: A single-centre retrospective cohort study  
*Salah M, Montasser IF, El Gendy HA, Korraa AA, Elewa GM, Dabbous H, Mahfouz HR, Abdelrahman M, Goda MH, Bahaa El-Din MM, El-Meteini M, Labib HA*

- 1162** Impact of alcohol consumption on treatment outcome of hepatocellular carcinoma patients with viral hepatitis who underwent transarterial chemoembolization

*Rattanasupar A, Chang A, Prateepchaiboon T, Pungpipattrakul N, Akarapatima K, Songjamrat A, Pakdeejit S, Prachayakul V, Piratvisuth T*

### Retrospective Study

- 1173** Relationship between phase angle, steatosis, and liver fibrosis in patients coinfecting with human immunodeficiency virus/hepatitis C virus

*Fernandes SA, Tovo CV, da Silva ALM, Pinto LP, Carteri RB, Mattos AA*

- 1182** DNA and RNA oxidative damage in hepatocellular carcinoma patients and mortality during the first year of liver transplantation

*Lorente L, Rodriguez ST, Sanz P, González-Rivero AF, Pérez-Cejas A, Padilla J, Díaz D, González A, Martín MM, Jiménez A, Cerro P, Portero J, Barrera MA*

- 1190** Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma

*Tajiri K, Ito H, Kawai K, Kashii Y, Hayashi Y, Murayama A, Minemura M, Takahara T, Shimizu Y, Yasuda I*

- 1200** Use of doppler ultrasound to predict need for transjugular intrahepatic portosystemic shunt revision

*Duong N, Healey M, Patel K, Strife BJ, Sterling RK*

### Observational Study

- 1210** Gut dysbiosis and body composition in cirrhosis

*Maslennikov R, Ivashkin V, Alieva A, Poluektova E, Kudryavtseva A, Krasnov G, Zharkova M, Zharikov Y*

- 1226** Prevalence of nonalcoholic fatty liver disease and its association with age in patients with type 2 diabetes mellitus

*Yamane R, Yoshioka K, Hayashi K, Shimizu Y, Ito Y, Matsushita K, Yoshizaki M, Kajikawa G, Mizutani T, Watarai A, Tachi K, Goto H*

### SYSTEMATIC REVIEWS

- 1235** Factors early in life associated with hepatic steatosis

*Quek SXZ, Tan EXX, Ren YP, Muthiah M, Loo EXL, Tham EH, Siah KTH*

### META-ANALYSIS

- 1248** Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis

*Loo JH, Xu WXF, Low JT, Tay WX, Ang LS, Tam YC, Thuraiarajah PH, Kumar R, Wong YJ*

- 1258** Spontaneous bacterial empyema in cirrhosis: A systematic review and meta-analysis

*Reiche W, Deliwala S, Chandan S, Mohan BP, Dhindsa B, Ramai D, Perisetti A, Rangray R, Mukherjee S*

**ABOUT COVER**

Editorial Board Member of *World Journal of Hepatology*, Lemonica Koumbi, MSc, PhD, Postdoctoral Fellow, Department of Nutritional Sciences and Dietetics, International Hellenic University (IHU), Thessaloniki 57400, Thessaloniki, Greece. lemonica.koumbi@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Hepatology* (*WJH*, *World J Hepatol*) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJH* mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

**INDEXING/ABSTRACTING**

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for *WJH* as 0.52. The *WJH*'s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Hepatology is 42/70.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Yi-Xuan Cai; Production Department Director: Xiang Li; Editorial Office Director: Xiang Li.

**NAME OF JOURNAL**

*World Journal of Hepatology*

**ISSN**

ISSN 1948-5182 (online)

**LAUNCH DATE**

October 31, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Nikolaos Pylsopoulos, Ke-Qin Hu, Koo Jeong Kang

**EDITORIAL BOARD MEMBERS**

<https://www.wjnet.com/1948-5182/editorialboard.htm>

**PUBLICATION DATE**

June 27, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Fibrosis regression following hepatitis C antiviral therapy

Aisha Elsharkawy, Reham Samir, Mohamed El-Kassas

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): 0  
Grade C (Good): C, C, C, C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** He F; Nevola R, Italy; Sagnelli C, Italy

**Received:** January 29, 2022

**Peer-review started:** January 29, 2022

**First decision:** April 10, 2022

**Revised:** April 16, 2022

**Accepted:** May 12, 2022

**Article in press:** May 12, 2022

**Published online:** June 27, 2022



**Aisha Elsharkawy, Reham Samir,** Department of Endemic Medicine and Hepatogastroenterology, Faculty of Medicine, Cairo University, Cairo 11566, Egypt

**Mohamed El-Kassas,** Department of Endemic Medicine, Faculty of Medicine, Helwan University, Cairo 11795, Egypt

**Corresponding author:** Mohamed El-Kassas, MD, MSc, PhD, Professor, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Helwan, Cairo 11795, Egypt. [m\\_elkassas@hq.helwan.edu.eg](mailto:m_elkassas@hq.helwan.edu.eg)

### Abstract

Hepatitis C virus (HCV) infection is one of the most common causes of liver pathology. It is a major etiological factor of continuous liver injury by triggering an uncontrolled inflammatory response, causing liver fibrosis and cirrhosis. Liver fibrosis is a dynamic process that can be reversible upon timely cessation of the injurious agent, which in cases of HCV is represented by the sustained virological response (SVR) following antiviral therapies. Direct-acting antiviral therapy has recently revolutionized HCV therapy and minimized complications. Liver fibrosis can be assessed with variable invasive and non-invasive methods, with certain limitations. Despite the broad validation of the diagnostic and prognostic value of non-invasive modalities of assessment of liver fibrosis in patients with HCV, the proper interpretation of liver stiffness measurement in patients after SVR remains unclear. It is also still a debate whether this regression is caused by the resolution of liver injury following treatment of HCV, rather than true fibrosis regression. Regression of liver fibrosis can possess a positive impact on patient's quality of life reducing the incidence of complications. However, fibrosis regression does not abolish the risk of developing hepatocellular carcinoma, which mandates regular screening of patients with advanced fibrosis.

**Key Words:** Fibrosis regression; Hepatitis C virus; Direct-acting antivirals; Hepatocellular carcinoma; Liver fibrosis; Cirrhosis

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.



**Core Tip:** Hepatitis C virus (HCV) infection is one of the most common causes of hepatitis that results in continuous liver injury. Uncontrolled inflammatory responses result in liver fibrosis and cirrhosis. Liver fibrosis is a dynamic process that can be reversible upon timely cessation of the injurious agent. In cases of HCV, achievement of sustained virological response by antiviral therapies might be accompanied by regression of liver fibrosis and improvement of the patient's clinical profile. Assessment of liver fibrosis can be done with invasive and non-invasive methods, with certain limitations. Fibrosis regression can positively impact patients' quality of life, reducing complications.

**Citation:** Elsharkawy A, Samir R, El-Kassas M. Fibrosis regression following hepatitis C antiviral therapy. *World J Hepatol* 2022; 14(6): 1120-1130

**URL:** <https://www.wjgnet.com/1948-5182/full/v14/i6/1120.htm>

**DOI:** <https://dx.doi.org/10.4254/wjh.v14.i6.1120>

## INTRODUCTION

Hepatitis C virus (HCV) infection is a major causative agent incriminated in liver pathology. It commonly causes progressive liver disease that ranges from chronic inflammation to fibrosis and cirrhosis, with its complications including hepatocellular carcinoma (HCC). A long-term, persistent and uncontrolled inflammatory response is the hallmark of such diseases, leading to hepatic injury and more serious disease progression[1]. Chronic infection develops in around 85% of infected patients. According to the World Health Organization, about 71 million individuals worldwide are chronically infected with HCV, and mortality because of HCV-related hepatic complications approaches 0.39 million infected people annually. A major complication of HCV is liver fibrosis; and there is an ongoing need of better assessment of hepatic fibrosis with different accurate modalities[2]. Also, discovering an effective antiviral therapy was a major target for research, and fibrosis regression following treatment was a substantial challenge[3]. With the evolution of INF-free direct-acting antivirals (DAAs) has; the natural history of chronic hepatitis C has been modulated and now viral cure has become much more feasible[4].

## HCV AND LIVER FIBROSIS

Following infection with HCV, the immune responses in the liver are initiated by hepatocytes, Kupffer cells, hepatic stellate cells (HSCs) and immune cells (macrophages, mast cells, dendritic cells, and natural killer cells) recruited to the liver, causing spontaneous elimination of acute HCV infection. However, failure of the immune responses to eliminate the virus is documented in 70%-80% of cases during the acute phase, leading to chronic infection[5]. HSCs respond to a variety of extracellular signals that drive the fibrogenic response. Recent single-cell RNA sequencing studies have shown remarkable variability in HSCs and identified unique markers for different HSC subtypes[6].

Persistent HCV replication in hepatocytes triggers uncontrolled inflammation and production of excessive inflammatory cytokines, which exacerbates tissue damage (1) and stimulates the quiescent HSCs, leading to their activation and differentiation into myofibroblasts. Myofibroblasts are the main cells responsible for triggering fibrogenesis and the formation of various extracellular matrix (ECM) components in order to repair damaged tissues[7]. Because of increased cross-linking by tissue transglutaminases and resistance to proteolysis by metalloproteinases, the ensuing liver damage speeds up the thickening of septae, preventing the total regression of fibrosis. Furthermore, excessive ECM deposition leads to scar development, which may generally be corrected by fibrolysis. ECM deposition and breakdown alternate in the progression of liver fibrosis. When hepatic damage persists, fibrogenesis finally outpaces the liver's ability for scar clearance, and extracellular matrix accumulates[8]. However, liver fibrosis can be reversible following the resolution of HCV infection early. This potential reversibility decreases by the chronic persistent damage-causing fibrogenesis besides insufficient fibrinolysis even if HCV infection has resolved. At this point, fibrosis becomes irreversible and more progressive ending toward LC clearance of activated HSCs through apoptosis is a determining factor for liver fibrosis regression in chronic HCV patients[9]. Despite the remarkable efficacy of currently used direct-acting antivirals (DAAs) in eradicating HCV in over 95% of cases, this does not signify a cure from late-stage fibrosis or cirrhosis[10]. Infected individuals with HCV-associated fibrosis and viremia may need further therapy to effectively resolve liver damage caused by the virus.

## FIBROSIS REGRESSION FOLLOWING HCV TREATMENT: DOES FIBROSIS REALLY REGRESS?

The exact definition of fibrosis regression has not been properly established, but it shows a reduction in fibrosis content. However, this definition does not consider the other changes in liver architecture, including changes in nodule size, the extent of terminal venular collapse, elements of regeneration, or altered types or distributions of collagen and other ECM components, especially in cirrhotic liver. Neither is there a standardized definition of "clinically significant fibrosis regression." However, it is proposed that the concept is most often used to describe fibrosis regression that is adequate to improve clinical outcomes and decrease the risk of decompensation and consequences associated with portal hypertension. Studies that have characterized fibrosis regression following DAAs have only followed patients for 2-3 years, hindering the possibility of tracking long-term histologic changes after sustained virological response rates (SVR)[11]. However, most of these studies documented significant fibrosis regression following DAA therapy[12,13]. Tables 1 and 2 show review of different studies assessing fibrosis outcome and hepatic histological changes following DAA therapy[13-37]. Interestingly, fibrosis regression has been proved to continue as far as years following viral eradication; however, fibrosis regression was mainly documented shortly after end of treatment (EOT) partly due to lack of long term follow up. Several recent studies though could manage to follow HCV patients years following viral eradication to clarify this issue[11,18,23].

At the cellular level, variable mechanisms may explain the process of fibrosis regression. Most processes linked to fibrosis regression have been more described than the final destiny of activated HSCs following damage resolution, albeit mostly in animal models. In animal studies, three routes of HSC responses during regression have been identified: (1) Return to a state of inactivity; (2) Apoptosis/autophagy; and (3) Cellular senescence. HSCs may return from an active to a quiescent state [38]. The reversion or inactivation of HSCs reflects that the cells move to an inactivated state when liver injury resolves, yet they retain the ability to reawaken faster than fully dormant cells. Such data raise the possibility that reverted HSCs might contribute to the regression of fibrosis, but may promote a rapid progression of fibrosis and a severe recurrence of liver injury[39]. Aging, obesity, diabetes, and other variables have been linked to prolonged liver inflammation and fibrosis after hepatitis C SVR[18]. With the discovery of the Tcf21 transcription factor in mice, as well as additional transcription factors involved in HSC quiescence, such as GATA 4/6, Lhx2, RAR, IRF 1/2, PPAR, ETS 1/2, GR, and NF1, the molecular basis for inactivation has recently been studied[40].

Fibrosis regresses, both in experimental and animal models. Eradication of the causative agent of liver fibrosis is the most appropriate way for the resolution of fibrosis by inducing remodeling of liver vascular architecture and regaining the normal lobular architecture. At some point, liver fibrosis may be reversed by removing the offending cause of liver disease. Regression of liver fibrosis was documented upon early management of cases of autoimmune hepatitis, or hepatitis B virus (HBV) infection[41]. The evolutions of variable inflammatory cascades, activated cells, and fibrogenic cytokines have been postulated as the driving force in liver fibrosis[11]. Similarly, fibrosis regression is associated with myofibroblast deactivation, collagenase enzyme activation, fibrillar cellular matrix disintegration, cell death (senescence and apoptosis of active stellate cells), and fibrous septa resorption[42]. Cirrhosis is a more complicated form of end-stage fibrosis that includes angiogenesis, necro-inflammatory alterations, innate immunity, oxidative stress, tissue hypoxia, and bacterial translocation[43]. The likelihood of fibrosis remission rather than cirrhosis remission is high. However, reversing liver fibrosis does not ensure that the problematic chemical will be removed. The age of an individual, genetic and epigenetic factors, rate of fibrosis progression (slow or rapid fibrosis), and disease-related factors like the etiology and staging of chronic liver disease are all factors that influence the fibrosis regression process. Other possible factors that may cause arrest in fibrosis regression or even cause progression such as liver steatosis with inflammation, alcohol use and diabetes mellitus working as contributing factors for liver injury and fibrosis[18,21]. According to Soliman *et al*[20], 2020; scores of fibrosis regression shows more regression in patients with lower degrees of steatosis and lower body mass index (BMI).

Interference must occur at a certain period for liver fibrosis to be reversible; otherwise, no regression is foreseeable. The "point of no return," or the moment at which the liver is sufficiently damaged that SVR will not reverse the illness, has yet to be defined. It is at this point that liver fibrosis progresses inexorably[20]. It's debatable whether progression and regression rates are connected, indicating that people who advance faster may also regress faster[11]. Despite the lack of evidence, most specialists feel that major regression is unlikely after severe architectural distortion, vascular collapse, and portal hypertension have occurred. This might be due to collagen's substantial structural cross-linking. As the collagen bands develop, the fibrotic bands are mostly fibrillar collagen. Some of these cross-links are permanent and cannot be destroyed by conventional collagenases, indicating that fibrosis development is unavoidable[44]. As a result, there is limited evidence that extensive areas of parenchymal extinction may be repopulated by regenerated hepatocytes, and vascular lesions in liver cirrhosis often remain with little evidence of full recovery to normal microcirculation in cirrhotic livers[45].

In the IFN era, before deciding for treatment choices, a liver biopsy was the gold standard for appropriate liver fibrosis staging. The majority of studies used paired liver samples to assess fibrosis

**Table 1 Studies illustrating outcome of liver fibrosis following hepatitis C virus clearance with direct-acting antivirals therapy**

Ref.	Therapy	n	Follow-Up	Method of fibrosis assessment	Outcome
Knop <i>et al</i> [14], 2016	DAA	54	24 wk	TE, ARFI	- 88% achieved an improvement of LS values at FU24; - 46% showed reduction in liver stiffness higher than 30% at FU24
Bachofner <i>et al</i> [15], 2016	DAA	392	18 mo	TE, FIB-4 and APRI scores, histopathological results were recorded if available	- Overall TE values of the included patients significantly decreased (regression of 32.4%); - Median FIB-4 and APRI values significantly decreased from 2.54 and 1.10 to 1.80 and 0.43
Dolmazashvili <i>et al</i> [16], 2017	INF-based/DAA	304	24 wk	TE	- 65.1% achieved at least a 20% reduction in LS; - Overall proportion of patients with stage F4 decreased from 56.6% to 36.5%
Pietsch <i>et al</i> [17], 2018	DAA	143	24 and 96 wk	TE, FIB-4 and APRI	-A short-term reduction in LS until FU24 was seen in almost every patient regardless of stage of liver disease; -Further regression was seen in patients with early cirrhosis but not in individuals with cirrhosis and impaired liver function; -Progression of LS values occurred despite viral clearance in about one-sixth of the patients (17%)
Hedenstierna <i>et al</i> [18], 2018	DAA	269	7.7 yr	TE	- A majority improved their fibrosis stage after SVR; - 24% had persisting advanced fibrosis with a LS level of $\geq 9.5$ kPa
Lledó <i>et al</i> [19], 2018	DAA	260	SVR12	TE	Significant fibrosis regression in 40% of the cohort patients more pronounced in patients with baseline advanced fibrosis and cirrhosis
Soliman <i>et al</i> [20], 2020	DAA/ INF-based	180 DAA/ 180 INF-based	at SVR12, 6 mo and 1 yr	TE	Reduction in fibrosis was reported in; 46.7% and 49.3% of patients with moderate fibrosis, and 89% and 78.7% of patients with advanced fibrosis after one yr of INF containing and INF free DAAs regimens respectively
Shiha <i>et al</i> [21], 2020	DAA	2326	12-45 mo	TE, and (FIB-4, FIB-5 and APRI)	- In cirrhotic patients, 21.8% showed reversal of cirrhosis, 27.4% showed fibrosis regression while 50.8% remained stationary; - About 26.5% of F3 patients showed reversal of fibrosis, 31.5% showed fibrosis regression and 30.6% remained stationary while 11.4% progressed to F4
Hablass <i>et al</i> [22], 2021	DAA	137	12 mo	TE, and FIB-4	In all patients, the FIB-4 and TE values after HCV elimination was significantly lower than its mean values at baseline
El-Kady <i>et al</i> [23], 2021	DAA	300	2 yr	TE	Both HCV treatment regimens showed improvement in liver fibrosis
Zakareya <i>et al</i> [13], 2021	DAA	655	1, 3, and 5 yr	TE	There was an overall significant regression of liver stiffness in all patients after sustained HCV eradication
Agwa <i>et al</i> [24], 2022	DAA	1230	12 and 48 wk	TE, FIB-4	- 42.7% F4 patients improved and became (190) F3, (90) F2, and (220) F1; - 40 of 60 F3 patients improved and became (10) F2 and (30) F1; - 28.4% off the treated patients transited from significant fibrosis ( $\geq$ F3) to non-significant fibrosis ( $\leq$ F2)
Hassanin <i>et al</i> [25], 2022	DAA	162	48 wk	TIMP-1, FIB-4 and TE	Liver fibrosis was improved as evidenced by significant decline in serum level of TIMP-1, significant improvement in Fib-4 score, and significant decline in LSM
Thanapirom <i>et al</i> [26], 2022	DAA	89	1 yr	TE, SWE, and MRE	Viral eradication resulted in the reduction of LS values as evaluated by three elastography techniques
Rosato <i>et al</i> [27], 2022	DAA	516	24 mo	TE	- LS significantly decreased till SVR with a progressive reduction until 24 mo; - Only patients with steatosis and those who developed HCC did not experience a late improvement in LS
Yoo <i>et al</i> [28], 2022	DAA	112	48, 96 and 144 wk	TE, FIB-4 and APRI	LS value in patients achieving SVR significantly decreased over time ( $19.4 \pm 12.9$ kPa [baseline], $13.9 \pm 9.1$ kPa [48 wk], $11.7 \pm 8.2$ kPa [96 wk], $10.09 \pm 6.23$ [144 wk])

DAA: Direct acting antiviral; INF: Interferon; TE: Transient elastography; ARFI: Acoustic Radiation Force Impulse; LSM: Liver stiffness measurement; SWE: Shear wave elastography; MRE: Magnetic resonance elastography; SVR: Sustained virological response; HCC: Hepatocellular carcinoma; TIMP-1: Tissue inhibitor of metalloproteinases-1.

changes after therapy. Several studies proved that fibrosis regression was documented in patients receiving IFN therapy by liver biopsy and non-invasive liver fibrosis parameters[32,46]. In the DAA era, dynamics of fibrosis regression following SVR have not been well identified, particularly because liver biopsy is infrequently performed. The quantity of fibrosis and its physical distribution, other underlying disorders, environmental or hereditary variables, and the variable elements that drive fibrosis advancement may all influence fibrosis regression. There have been no studies to discover genetic



**Table 2 Studies illustrating hepatic histological changes following hepatitis C virus clearance with direct acting antiviral therapy**

Ref.	Therapy	n	Follow-up	Scores utilized	Outcome
Shiratori <i>et al</i> [29], 2000	INF-based	487	Median of 3.7 yr apart (range, 1 to 10 yr)	Criteria of Desmet and colleagues (F0 to F4) and those of the French METAVIR Cooperative Study Group (A0 to A3)	- A mean reduction in fibrosis score of -0.60+/-0.07 at less than 3 yr of follow-up and -0.88+/-0.08 at 3 yr or more of follow-up; - Reversal of cirrhosis among 11 CHC patients; - Seven patients decreased their level of fibrosis from F4 to F2 and four from F4 to F3
Poynard <i>et al</i> [30], 2002	INF-based	1030	20 mo mean duration between the biopsies	METAVIR scoring system	- Reversal and/or regression of cirrhosis occurred in 49% of patients where 15% regressed to stage 3, 16% reversed to stage 2, 15% reversed to stage 1 and 2% reversed to stage 0; - Fibrosis worsened in 15%
Maylin <i>et al</i> [31], 2008	INF-based	126	3.27 yr	METAVIR scoring system	- Fibrosis stage was improved in 56%, stable in 32%, progressed in 12%; - Regression of cirrhosis was observed in 64% patients; - No cirrhosis decompensation was observed, and 3 patients developed HCC
George <i>et al</i> [32], 2009	INF-based	49	5 yr	METAVIR scoring system	- 82% had a decrease in fibrosis score, and 92% had a decrease in combined inflammation score; - Two patients with pretreatment cirrhosis developed HCC and one died; - All the other patients with pretreatment cirrhosis or advanced fibrosis had improved fibrosis scores on long-term follow-up biopsy
D'Ambrosio <i>et al</i> [33], 2012	INF-based	38	61 mo	METAVIR scoring system, and the area of fibrosis was measured using morphometry	- Reversal of cirrhosis in 23.6% of the patients, regression of cirrhosis in 61%; regression of fibrosis in 36% of CHC patients
Enomoto <i>et al</i> [34], 2018	DAA	20 paired biopsy specimen	41 ± 20 wk	Knodel scoring system and the METAVIR scoring system	- The inflammation grade significantly regressed, but the fibrosis stage did not; - Histological improvement, defined as a ≥ 2-point decrease in the Knodel inflammatory score and no worsening of the fibrosis, was found 55% patients.
Pan <i>et al</i> [35], 2018	INF-based/DAA	15	3 yr	METAVIR and Batts - Ludwig grading systems	- 13 of patients had improved liver stiffness (to < 9.5 kPa)
Chu <i>et al</i> [36], 2019	INF-based	31	93 mo	METAVIR scoring system and HAI	- Fibrosis regression, stable, and progression were 19%, 45%, and 36%; - A total of 71% of patients achieved inflammation improvement, whereas 6% and 23% of patients had stable disease and disease-progression, respectively
Cheng <i>et al</i> [37], 2021	DAA	21	6 mo	METAVIR fibrosis score and HAI	- Fibrosis scores improved in 61.9% of the patients; - 24.8% stable course; - 14.3% progression of fibrosis

DAA: Direct acting antiviral; INF: Interferon; HAI: Histological Activity Index; HCC: Hepatocellular carcinoma; CHC: Chronic hepatitis C.

factors of fibrosis regression, including single nucleotide polymorphisms, since so few patients have received liver biopsy following HCV SVR due to its limitations[11]. The popularity of non-invasive methods of liver fibrosis staging was related to the advancement of DAA treatments, which had abolished the role of liver biopsy. As a result, most current research looking for fibrosis regression rely on paired or bi-paired non-invasive methods[47,48].

Despite the broad validation of the diagnostic and prognostic value of non-invasive modalities of liver fibrosis assessment, including liver stiffness measurement (LSM) in patients with HCV. LSM is a widely used non-invasive tool for the diagnosis and assessment of degrees of liver fibrosis and has high accuracy[49]. The proper interpretation of LSM in patients after SVR remains unclear. Many studies have shown a substantial reduction in LSM following SVR in HCV patients treated with DAAs[50-52]. It's still unclear if the drop in LSM after HCV eradication is due to HCV's necro-inflammatory activity being suppressed and changes in hepatic inflammation, rather than the regression of liver fibrosis. However, a large Canadian cohort of HIV-HCV co-infected patients that prospectively evaluated long-term changes in LSM before and after SVR due to DAAs confirmed that LSM after SVR likely indicates a true fibrosis reversal[53].

## ANTIVIRAL TREATMENT FOR HCV

Introducing the INF-free DAA has changed the natural history of chronic HCV in the past decade and revolutionized HCV treatment and viral cure. Indeed, improved quality of life is now a reality in most of patients. DAA regimens are safe and highly effective, resulting in SVR higher than 90%[4]. The last therapeutic regimens approved by Food and Drug Administration and European Medicines Agency are pan-genotypic, once-daily, all-oral DAA combinations that have the potential to close the gaps in the

current DAA treatment portfolio. Eight-twelve wk of treatment is now the standard of care, and viral eradication can be achieved in > 95% across different patient populations[54]. As a result, major scientific recommendations have been modified to promote DAA medication for all people who have chronic hepatitis C[4]. Furthermore, a recent large cohort research found that DAA therapy is linked to a lower risk of death and hepatocellular carcinoma (HCC), confirming SVR's long-term impact[55]. However, the risk of liver-related events persists in patients with HCV who have cleared the virus, particularly in those who had advanced fibrosis and cirrhosis prior to treatment[11].

## EVALUATION OF FIBROSIS

In the INF era, liver biopsy was the most accurate approach for making treatment choices as a precise assessment of liver fibrosis[56]. Therefore, the variable protocols of DAA therapies for HCV treatment had adopted reliance on non-invasive modalities of assessment of liver fibrosis. However, the existing non-invasive clinical and laboratory scores for assessing liver fibrosis performed poorly and inaccurately, failing to separate the phases of liver fibrosis' dynamic progression. Additionally, sophisticated imaging methods such as transient elastography (TE), shear wave (SW), acoustic radiation force impulse elastography (ARFI), and magnetic resonance elastography are available to quantify liver stiffness (LS) utilising a fibroscan instrument (MRE)[57]. However, it is important to interpret LSM cautiously as many studies denoted that liver stiffness could be affected by the presence of hepatic steatosis; and that the presence of severe steatosis, detected by histology or by US, should always be taken into account in order to avoid overestimations of liver stiffness[58,59]. In fact, higher LSM values in the presence of liver steatosis have been reported in patients with chronic HCV[60]. It was also reported that high body mass index BMI values negatively affected the diagnostic reliability[61]. Other limitations include the presence of tissue abnormalities, such as edema or inflammation which can interfere with LSM, independently of fibrosis stressing that LSM should be cautiously interpreted in such cases[62].

Finally, there is no perfect single test solution, as serological markers are good at assessing the advanced fibrosis stages only, making them inaccurate in mild to moderate fibrosis cases. So, it was suggested to use two non-invasive methods for assessing liver fibrosis, one imaging and the other serum marker, to be more effective and reliable[2]. Despite the high costs, time-consuming matter, and refusal of some patients, MRI elastography is a promising and more accurate tool for assessing liver fibrosis[47].

A widely accessible, reliable, accurate, reproducible, simple, and dynamic assessment of liver fibrosis development and reversal is still needed. In hepatology research, this seems to be an unmet need. Because the quantity of deposited collagens in each stage are not multiples of the preceding stage, the difference between liver fibrosis stages is a qualitative rather than a quantitative linear measure[63]. Late stages of fibrosis need more collagenases than early stages. Similarly, the non-uniform deposition of collagen in connection to time intervals is obvious, and variations in LS measurement in later stages may be within the same stage of fibrosis for the large number of people included[64].

## HISTOPATHOLOGICAL FEATURES OF FIBROSIS REGRESSION

There is no agreement on the suggested histological staging system for chronic viral hepatitis after therapy. Histological examination is best done on paired liver samples, one taken before treatment begins and the other taken at least six mo after the end of treatment (EOT). Fibrosis regression was formerly defined as a drop of at least one point in either the METAVIR or the histological activity index score from baseline to post-treatment assessment. The four-stage METAVIR fibrosis grading system was used to determine the fibrosis stage[37]. Stage 4 cirrhosis is further split into three categories based on fibrous septa thickness and nodule size, which correctly associated with clinical stage and the probability of hepatocellular carcinoma recurrence following curative resection[65]. Another scoring method is the hepatic repair complex, which is based on important histology features that indicate cirrhosis regression. The delicate perforated septa, isolated thick collagen fibres, thin peri-portal fibrous spikes, hepatic vein remnants with prolapsed hepatocytes, split septa interrupted by clusters or cords of hepatocytes, and aberrant parenchymal vein are all histological observations that support this system [66]. The Beijing classification, P-I-R Score, is a novel tool for dynamic assessment of fibrosis advancement versus regression (predominantly regressive, indeterminate, and predominantly progressive). This system was proposed by Sun *et al*[66] to evaluate chronic HBV before and after treatment[67].

More rigorous efforts are still required to respect the heterogeneous nature of the cirrhosis process to incorporate regression features and formulate a valid scoring system for better evaluation of fibrosis and activity regression in chronic liver diseases. In the assessment of fibrosis regression after HCV therapy, however, the improvement of digital pathology and the introduction of morphometry in determining collagen proportional area was noteworthy. Furthermore, second-harmonic generation/

two-photon excitation fluorescence (SHG/TPEF), a quantitative measure of liver fibrosis width, is thought to be the most accurate predictor of fibrosis regression[33].

Multiple studies addressed fibrosis regression following HCV treatment with IFN and DAAs using invasive and non-invasive tools as shown in table 1 and 2. Conversely, reversal of liver inflammation and fibrosis was achieved in a significant number of patients treated with DAAs using histological assessment by liver biopsy[13-37].

## HEPATOCELLULAR CARCINOMA (HCC) POST-DAAS AND RELATION TO FIBROSIS REGRESSION

A 76% reduction in the risk of developing HCC in patients achieving SVR following IFN therapy has been documented by a meta-analysis[68]. However, some studies have pointed out that DAAs could instead augment the development of HCC. Despite the conflicting data regarding this issue in many studies, it was settled that HCV eradication has a protective effect against HCC development, regardless antiviral therapy. Response to treatment (SVR or non-SVR) was the sole independent predictor of HCC recurrence following curative treatment, rather than the type of antiviral treatment (IFN or DAA)[69].

Following the achievement of SVR, fibrosis regression reached its plateau for about one year. In addition, the fibrosis regression does not prevent the development of HCC years after treatment as liver, although deprived of the pro-inflammatory viral trigger, still has a potentially carcinogenic persistence [70,71]. Therefore, because of the insufficient data regarding the decrease in HCC risk after SVR with DAAs, patients, especially those with severe fibrosis, should be committed to frequent HCC screening.

## EFFECT OF FIBROSIS REGRESSION ON CLINICAL OUTCOMES

There is strong accumulating evidence that HCV eradication in all patients, besides patients with baseline cirrhosis, leads to improved clinical outcomes. A wide range of effects of HCV elimination exist. These include an overall reduction in mortality and the risk of HCC in patients with advanced fibrosis, and a reduction in extrahepatic manifestations, *e.g.*, HCV-related non-Hodgkin's lymphoma, other lymphoproliferative disorders, and cryoglobulinemic vasculitis[72,73]. Additionally, DAA-induced HCV clearance has been shown to decrease the risk of cardiovascular events in addition to the incidence of type 2 DM incidence probably by restoring the disordered glucose homeostasis[74,75]. Improvement in fibrosis, which seems to be a main driver of cirrhosis sequelae, will almost certainly lead to clinical improvement, even in patients with portal hypertension[11]. The long-term effects of fibrosis regression, however, are yet unknown. Furthermore, it has to be determined if the improved clinical outcome is due to successful causative therapy or fibrosis regression. Wu *et al*[76] looked at patients with compensated cirrhosis precipitated by HBV and found that changes in LS throughout the first 26 wk might predict decompensations and HCC with antiviral therapy. This might indicate that fibrosis regression has clinical implications. Cirrhosis regression was linked to lower morbidity and increased mortality in another HCV retrospective study[77]. However, there is currently a dearth of direct and convincing evidence that biopsy-proven fibrosis regression improves clinical outcomes. The more serious the underlying liver disease (particularly in individuals with advanced fibrosis and portal hypertension), the less likely the patient is to evade problems. Some individuals with severe liver disease and sequelae, on the other hand, may improve[11].

## CONCLUSION

Despite the amazing progress in HCV treatment using DAAs, information about its role in fibrosis regression is still inadequate. If the non-invasive methods for assessing liver fibrosis are suitable for assessing regression, it needs much research. Regression of liver fibrosis in cirrhotic patients and those with advanced fibrosis will remain a hope that both physicians and patients seek.

## FOOTNOTES

**Author contributions:** All authors equally contributed to this paper with conception and design of the work, literature review, drafting and critical revision, editing, and final approval of the final version of the manuscript.

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Egypt

**ORCID number:** Aisha Mahmoud Elsharkawy 0000-0002-7150-173X; Reham Samir 0000-0001-7469-6483; Mohamed El-Kassas 0000-0002-3396-6894.

**Corresponding Author's Membership in Professional Societies:** Egyptian Association for Research and Training in Hepatogastroenterology, No. 001.

**S-Editor:** Wang LL

**L-Editor:** A

**P-Editor:** Wang LL

## REFERENCES

- Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. *World J Gastroenterol* 2018; **24**: 5297-5311 [PMID: 30598575 DOI: 10.3748/wjg.v24.i47.5297]
- Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. *Future Sci OA* 2018; **4**: FSO250 [PMID: 29255622 DOI: 10.4155/fsoa-2017-0083]
- World Health Organization. WHO fact sheet on infertility. Global Reproductive Health: Spring 2021, 6: e52 [DOI: 10.1097/grh.000000000000052]
- European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol* 2018; **69**: 461-511 [DOI: 10.1111/dme.13565]
- Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. *J Hepatol* 2014; **61**: S14-S25 [PMID: 25443342 DOI: 10.1016/j.jhep.2014.06.035]
- Dobie R, Wilson-Kanamori JR, Henderson BEP, Smith JR, Matchett KP, Portman JR, Wallenborg K, Picelli S, Zagorska A, Pendem SV, Hudson TE, Wu MM, Budas GR, Breckenridge DG, Harrison EM, Mole DJ, Wigmore SJ, Ramachandran P, Ponting CP, Teichmann SA, Marioni JC, Henderson NC. Single-Cell Transcriptomics Uncovers Zonation of Function in the Mesenchyme during Liver Fibrosis. *Cell Rep* 2019; **29**: 1832-1847.e8 [PMID: 31722201 DOI: 10.1016/j.celrep.2019.10.024]
- Sebastiani G, Gkouvatso K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. *World J Gastroenterol* 2014; **20**: 11033-11053 [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033]
- Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. *United European Gastroenterol J* 2019; **7**: 642-650 [PMID: 31210942 DOI: 10.1177/2050640619840149]
- Friedman SL. Evolving challenges in hepatic fibrosis. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 425-436 [PMID: 20585339 DOI: 10.1038/nrgastro.2010.97]
- El Kassas M, Elbaz T, Hafez E, Esmat G. Safety of direct antiviral agents in the management of hepatitis C. *Expert Opin Drug Saf* 2016; **15**: 1643-1652 [PMID: 27661100 DOI: 10.1080/14740338.2017.1240781]
- Rockey DC, Friedman SL. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. *Gastroenterology* 2021; **160**: 1502-1520.e1 [PMID: 33529675 DOI: 10.1053/j.gastro.2020.09.065]
- El-Garem H, AbdAllah M, Omar H, Cordie A, Abdel Alem S, Mohey Eldin Elzahry MA, Ghaith D, Abou El-Soud NH, Kamal W, Elsharkawy A, Esmat G. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. *Expert Rev Gastroenterol Hepatol* 2019; **13**: 693-698 [PMID: 31043104 DOI: 10.1080/17474124.2019.1614441]
- Zakareya T, Elhelbawy M, Elzohry H, Eltabbakh M, Deif M, Abbasy M. Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients. *Can J Gastroenterol Hepatol* 2021; **2021**: 4961919 [PMID: 34589447 DOI: 10.1155/2021/4961919]
- Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-Rust M, Sarrazin C, Zeuzem S, Welker MW. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. *J Viral Hepat* 2016; **23**: 994-1002 [PMID: 27500382 DOI: 10.1111/jvh.12578]
- Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, Braun D, Seifert, B, Moncssek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terziroli Beretta-Piccoli B and Mertens JC. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. *Liver Int* 2017; **37**: 369-376 [DOI: 10.1111/liv.13256]
- Dolmazashvili E, Abutidze A, Chkhartishvili N, Karchava M, Sharvadze L, Tsertsvadze T. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. *Eur J Gastroenterol Hepatol* 2017; **29**: 1223-1230 [PMID: 28857900 DOI: 10.1097/MEG.0000000000000964]
- Pietsch V, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, Gebel M, Manns MP, Wedemeyer H, Potthoff A. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment



- with direct-acting antivirals. *United European Gastroenterol J* 2018; **6**: 1188-1198 [PMID: 30288281 DOI: 10.1177/2050640618786067]
- 18 **Hedenstierna M**, Nangarhari A, El-Sabini A, Weiland O, Aleman S. Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C. *J Viral Hepat* 2018; **25**: 802-810 [PMID: 29406590 DOI: 10.1111/jvh.12879]
  - 19 **Lledó, Gema M**; Carrasco, Itziar; Benítez-Gutiérrez, Laura M; Arias, Ana; Royuela, Ana; Requena, Silvia; Cuervas-Mons, Valentín; de Mendoza, Carmen. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. *AIDS* 2018; **32**: 2347-2352
  - 20 **Soliman H**, Ziada D, Salama M, Hamisa M, Badawi R, Hawash N, Selim A, Abd-Elsalam S. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study. *Endocr Metab Immune Disord Drug Targets* 2020; **20**: 104-111 [PMID: 31448717 DOI: 10.2174/1871530319666190826150344]
  - 21 **Shiha, G**, Soliman, R, Mikhail, N, Ibrahim, A, Serwah, A-H, Khattab, M. Changes in hepatic fibrosis stages after achieving SVR following direct-acting anti-viral treatment: a prospective study. *GastroHep* 2020; **2**: 39-48 [DOI: 10.1002/ygh2.384]
  - 22 **Hablass FH**, Lashen SA, Mohamed EA. Liver Fibrosis Regression After Direct-Acting Antivirals for Hepatitis C Virus: A Prospective Study. *Journal of Gastroenterology and Hepatology Research* 2021; **10**: 3429-3434 [DOI: 10.1016/s2468-1253(18)30004-9]
  - 23 **El-Kady M**, El-Sahhar M, El-Azab T, Ali A. Effect of DAAs on improvement of liver fibrosis assessed by transient elastography and associated risk factors for accelerating liver fibrosis. *Benha Medical Journal* 2021; **38**: 972-983 [DOI: 10.21608/bmfj.2021.88790.1450]
  - 24 **Agwa RH**, Elgazzar MH, El-Zayyadi IA. Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection. *Egypt J Intern Med* 2022; **34**: 18 [DOI: 10.1186/s43162-022-00111-1]
  - 25 **Hassanin T**, Ibraheem H, Makhlof M, Mahmoud W, El-Ameen N, Kamal E. Non-invasive Evaluation of Liver Fibrosis Changes in Patients with Chronic Hepatitis C after Directly Acting Antiviral Drugs. *Afro-Egyptian Journal of Infectious and Endemic Diseases* 2022; **12**: 92-98
  - 26 **Thanapirom K**, Suksawatamnuay S, Tanpowpong N, Chaopathomkul B, Sriphoosanaphan S, Thaimai P, Srisoonthorn N, Treprasertsuk S, Komolmit P. Non-invasive tests for liver fibrosis assessment in patients with chronic liver diseases: a prospective study. *Sci Rep* 2022; **12**: 4913 [PMID: 35318425 DOI: 10.1038/s41598-022-08955-x]
  - 27 **Rosato V**, Ascione A, Nevola R, Fracanzani AL, Piai G, Messina V, Claar E, Coppola C, Fontanella L, Lombardi R, Staiano L, Valente G, Fascione MC, Giorgione C, Mazzocca A, Galiero R, Perillo P, Marrone A, Sasso FC, Adinolfi LE, Rinaldi L. Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. *J Viral Hepat* 2022; **29**: 26-34 [PMID: 34582610 DOI: 10.1111/jvh.13617]
  - 28 **Yoo HW**, Park JY, Kim SG, Jung YK, Lee SH, Kim MY, Jun DW, Jang JY, Lee JW, Kwon OS. Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents. *Sci Rep* 2022; **12**: 193 [PMID: 34996920 DOI: 10.1038/s41598-021-03272-1]
  - 29 **Shiratori Y**, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. *Ann Intern Med* 2000; **132**: 517-524 [PMID: 10744587 DOI: 10.7326/0003-4819-132-7-200004040-00002]
  - 30 **Poynard T**, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology* 2002; **122**: 1303-1313 [PMID: 11984517 DOI: 10.1053/gast.2002.33023]
  - 31 **Maylin S**, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, Giuily N, Castelnau C, Cardoso AC, Asselah T, Féray C, Nicolas-Chanoine MH, Bedossa P, Marcellin P. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. *Gastroenterology* 2008; **135**: 821-829 [PMID: 18593587 DOI: 10.1053/j.gastro.2008.05.044]
  - 32 **George SL**, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. *Hepatology* 2009; **49**: 729-738 [PMID: 19072828 DOI: 10.1002/hep.22694]
  - 33 **D'Ambrosio R**, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. *Hepatology* 2012; **56**: 532-543 [PMID: 22271347 DOI: 10.1002/hep.25606]
  - 34 **Enomoto M**, Ikura Y, Tamori A, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Murakami Y, Kawada N. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. *United European Gastroenterol J* 2018; **6**: 1391-1400 [PMID: 30386612 DOI: 10.1177/2050640618791053]
  - 35 **Chu CY**, Cheng CH, Chen HL, Lin IT, Wu CH, Lee YK, Bair MJ. Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response. *J Formos Med Assoc* 2019; **118**: 1129-1137 [PMID: 30472042 DOI: 10.1016/j.jfma.2018.11.005]
  - 36 **Pan JJ**, Bao F, Du E, Skillin C, Frenette CT, Waalen J, Alaparthy L, Goodman ZD, Pockros PJ. Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C. *Hepatol Commun* 2018; **2**: 1320-1330 [PMID: 30411079 DOI: 10.1002/hep4.1228]
  - 37 **Cheng CH**, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, Hu PJ, Bair MJ. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. *J Formos Med Assoc* 2021; **120**: 1259-1268 [PMID: 33339709 DOI: 10.1016/j.jfma.2020.11.018]
  - 38 **Troeger JS**, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, Pradere JP, Friedman RA, Schwabe RF. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. *Gastroenterology* 2012; **143**: 1073-83.e22 [PMID: 22750464 DOI: 10.1053/j.gastro.2012.06.036]
  - 39 **Salas, Tanya & Lozano Sepúlveda, Sonia & Rincon, Ana Rosa & Govea Salas, Mayela & Rivas-Estilla, Ana.** Mechanisms involved in liver damage resolution after hepatitis C virus clearance. *Medicina Universitaria* 2021 [DOI: 10.1016/j.medun.2021.06.001]



- 10.1016/j.rmu.2017.05.005]
- 40 **Wang S**, Friedman SL. Hepatic fibrosis: A convergent response to liver injury that is reversible. *J Hepatol* 2020; **73**: 210-211 [PMID: 32402525 DOI: 10.1016/j.jhep.2020.03.011]
  - 41 **Zoubek ME**, Trautwein C, Strnad P. Reversal of liver fibrosis: From fiction to reality. *Best Pract Res Clin Gastroenterol* 2017; **31**: 129-141 [PMID: 28624101 DOI: 10.1016/j.bpg.2017.04.005]
  - 42 **Povero D**, Busletta C, Novo E, di Bonzo LV, Cannito S, Paternostro C, Parola M. Liver fibrosis: a dynamic and potentially reversible process. *Histol Histopathol* 2010; **25**: 1075-1091 [PMID: 20552556 DOI: 10.14670/HH-25.1075]
  - 43 **Saffiotti F**, Pinzani M. Development and Regression of Cirrhosis. *Dig Dis* 2016; **34**: 374-381 [PMID: 27170391 DOI: 10.1159/000444550]
  - 44 **Wanless IR**, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. *Arch Pathol Lab Med* 2000; **124**: 1599-1607 [PMID: 11079009 DOI: 10.5858/2000-124-1599-ROHC]
  - 45 **Khan Shahbaz MD**, Saxena Romil MBBS, FRCPath (UK). Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review. *Advances In Anatomic Pathology* **28**: 408-414
  - 46 **Lucero C**, Brown RS Jr. Noninvasive Measures of Liver Fibrosis and Severity of Liver Disease. *Gastroenterol Hepatol (N Y)* 2016; **12**: 33-40 [PMID: 27330502]
  - 47 **Bradley C**, Scott RA, Cox E, Palaniyappan N, Thomson BJ, Ryder SD, Irving WL, Aithal GP, Guha IN, Francis S. Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. *Eur Radiol* 2019; **29**: 3100-3107 [PMID: 30506214 DOI: 10.1007/s00330-018-5788-1]
  - 48 **Fernandes FF**, Piedade J, Guimaraes L, Nunes EP, Chaves U, Goldenzon RV, Cardoso SW, Duarte J, Grinsztejn B, Veloso VG, Pereira G, Perazzo H. Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response. *J Gastroenterol Hepatol* 2019; **34**: 2187-2195 [PMID: 31062880 DOI: 10.1111/jgh.14707]
  - 49 **Boursier J**, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-Hubert I, Rousselet MC, Calès P, de Ledinghen V. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. *J Hepatol* 2016; **65**: 570-578 [PMID: 27151181 DOI: 10.1016/j.jhep.2016.04.023]
  - 50 **Elsharkawy A**, Alem SA, Fouad R, El Raziky M, El Akel W, Abdo M, Tantawi O, AbdAllah M, Bourliere M, Esmat G. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. *J Gastroenterol Hepatol* 2017; **32**: 1624-1630 [PMID: 28177543 DOI: 10.1111/jgh.13758]
  - 51 **El-Raziky M**, Khairy M, Fouad A, Salama A, Elsharkawy A, Tantawy O. Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens. *J Interferon Cytokine Res* 2018; **38**: 129-136 [PMID: 29565743 DOI: 10.1089/jir.2017.0137]
  - 52 **Piedade J**, Pereira G, Guimarães L, Duarte J, Victor L, Baldin C, Inacio C, Santos R, Chaves U, Nunes EP, Grinsztejn B, Veloso VG, Fernandes F, Perazzo H. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes. *Sci Rep* 2021; **11**: 11681 [PMID: 34083617 DOI: 10.1038/s41598-021-91099-1]
  - 53 **Kronfli N**, Young J, Wang S, Cox J, Walmsley S, Hull M, Cooper C, Martel-Laferrriere V, Wong A, Pick N, Klein MB; Canadian Coinfection Cohort Study Investigators. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression? *Clin Infect Dis* 2021; **73**: 468-477 [PMID: 32504083 DOI: 10.1093/cid/ciaa702]
  - 54 **Ghany MG**, Morgan TR; AASLD-IDSAS Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Hepatology* 2020; **71**: 686-721 [PMID: 31816111 DOI: 10.1002/hep.31060]
  - 55 **Carrat F**, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepathier cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. *Lancet* 2019; **393**: 1453-1464 [PMID: 30765123 DOI: 10.1016/S0140-6736(18)32111-1]
  - 56 **Ellis EL**, Mann DA. Clinical evidence for the regression of liver fibrosis. *J Hepatol* 2012; **56**: 1171-1180 [PMID: 22245903 DOI: 10.1016/j.jhep.2011.09.024]
  - 57 **Abdelsameea E**, Alsebaey A, Abdel-Razek W, Ehsan N, Morad W, Salama M, Waked I. Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C. *Eur J Gastroenterol Hepatol* 2020; **32**: 1553-1558 [PMID: 31972660 DOI: 10.1097/MEG.0000000000001672]
  - 58 **Petta S**, Maida M, Macaluso FS, Di Marco V, Cammà C, Cabibi D, Craxi A. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. *Hepatology* 2015; **62**: 1101-1110 [DOI: 10.1002/hep.27844]
  - 59 **Boursier J**, de Ledinghen V, Sturm N, Amrani L, Bacq Y, Sandrini J, Le Bail B, Chaigneau J, Zarski JP, Gallois Y, Leroy V, Al Hamany Z, Oberti F, Fouchard-Hubert I, Dib N, Bertrais S, Rousselet MC, Calès P; Multicentre group ANRS HC EP23 FIBROSTAR. Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. *J Gastroenterol* 2014; **49**: 527-537 [PMID: 23681425 DOI: 10.1007/s00535-013-0819-9]
  - 60 **Macaluso FS**, Maida M, Cammà C, Cabibbo G, Cabibi D, Alduino R, Di Marco V, Craxi A, Petta S. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. *J Hepatol* 2014; **61**: 523-529 [PMID: 24815874 DOI: 10.1016/j.jhep.2014.04.045]
  - 61 **Petta S**, Di Marco V, Cammà C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. *Alimentary Pharmacology & Therapeutics* 2011; **33**: 1350-1360 [DOI: 10.1111/j.1365-2036.2011.04668.x]
  - 62 **European Association for Study of Liver**. Asociacion Latinoamericana para el Estudio del Hígado. EASL-ALEH Clinical

- Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol* 2015; **63**: 237-264
- 63 **Masugi Y**, Abe T, Tsujikawa H, Effendi K, Hashiguchi A, Abe M, Imai Y, Hino K, Hige S, Kawanaka M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Sakamoto M. Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. *Hepatol Commun* 2018; **2**: 58-68 [PMID: [29404513](#) DOI: [10.1002/hep4.1121](#)]
  - 64 **Castéra L**, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005; **128**: 343-350 [PMID: [15685546](#) DOI: [10.1053/j.gastro.2004.11.018](#)]
  - 65 **Kim MY**, Cho MY, Baik SK, Park HJ, Jeon HK, Im CK, Won CS, Kim JW, Kim HS, Kwon SO, Eom MS, Cha SH, Kim YJ, Chang SJ, Lee SS. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. *J Hepatol* 2011; **55**: 1004-1009 [PMID: [21354227](#) DOI: [10.1016/j.jhep.2011.02.012](#)]
  - 66 **Sun Y**, Zhou J, Wang L, Wu X, Chen Y, Piao H, Lu L, Jiang W, Xu Y, Feng B, Nan Y, Xie W, Chen G, Zheng H, Li H, Ding H, Liu H, Lv F, Shao C, Wang T, Ou X, Wang B, Chen S, Wee A, Theise ND, You H, Jia J. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. *Hepatology* 2017; **65**: 1438-1450 [PMID: [28027574](#) DOI: [10.1002/hep.29009](#)]
  - 67 **Lo RC**, Kim H. Histopathological evaluation of liver fibrosis and cirrhosis regression. *Clin Mol Hepatol* 2017; **23**: 302-307 [PMID: [29281870](#) DOI: [10.3350/cmh.2017.0078](#)]
  - 68 **Conti F**, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J Hepatol* 2016; **65**: 727-733 [PMID: [27349488](#) DOI: [10.1016/j.jhep.2016.06.015](#)]
  - 69 **Cardoso H**, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira P, Lopes S, Silva M, Andrade P, Morais R, Coelho R, Macedo G. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. *J Hepatol* 2016; **65**: 1070-1071 [PMID: [27476768](#) DOI: [10.1016/j.jhep.2016.07.027](#)]
  - 70 **Khan R**, Velpari S, Koppe S. All Patients With Advanced Fibrosis Should Continue to Be Screened for Hepatocellular Carcinoma After Sustained Virological Response of Hepatitis C Virus. *Clin Liver Dis (Hoboken)* 2018; **12**: 137-139 [PMID: [30988930](#) DOI: [10.1002/cld.707](#)]
  - 71 **Rinaldi L**, Guarino M, Perrella A, Pafundi PC, Valente G, Fontanella L, Nevola R, Guerrera B, Iuliano N, Imparato M, Trabucco A, Sasso FC, Morisco F, Ascione A, Piai G, Adinolfi LE. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. *Dig Dis Sci* 2019; **64**: 3013-3019 [PMID: [30937719](#) DOI: [10.1007/s10620-019-05604-8](#)]
  - 72 **Moon AM**, Green PK, Rockey DC, Berry K, Ioannou GN. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. *Aliment Pharmacol Ther* 2020; **51**: 364-373 [PMID: [31773763](#) DOI: [10.1111/apt.15586](#)]
  - 73 **Adinolfi LE**, Petta S, Fracanzani AL, Nevola R, Coppola C, Narciso V, Rinaldi L, Calvaruso V, Pafundi PC, Lombardi R, Staiano L, Di Marco V, Solano A, Marrone A, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxi A, Sasso FC. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. *Diabetes Obes Metab* 2020; **22**: 2408-2416 [PMID: [32761721](#) DOI: [10.1111/dom.14168](#)]
  - 74 **Adinolfi LE**, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, Rinaldi L, Calvaruso V, Staiano L, Di Marco V, Marrone A, Pafundi PC, Solano A, Lombardi R, Sasso FC, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxi A. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. *Atherosclerosis* 2020; **296**: 40-47 [PMID: [32005004](#) DOI: [10.1016/j.atherosclerosis.2020.01.010](#)]
  - 75 **Rossi C**, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, Wong J, Darvishian M, Bartlett S, Samji H, Yu A, Binka M, Alvarez M, Adu PA, Tyndall M, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. *J Hepatol* 2019; **71**: 1116-1125 [PMID: [31433302](#) DOI: [10.1016/j.jhep.2019.07.021](#)]
  - 76 **Wu S**, Kong Y, Piao H, Jiang W, Xie W, Chen Y, Lu L, Ma A, Xie S, Ding H, Shang J, Zhang X, Feng B, Han T, Xu X, Huo L, Cheng J, Li H, Wu X, Zhou J, Sun Y, Ou X, Zhang H, You H, Jia J. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis. *Liver Int* 2018; **38**: 1045-1054 [PMID: [29119705](#) DOI: [10.1111/liv.13623](#)]
  - 77 **Ehsan N**, Sweed D, Elsabaawy M. Evaluation of HCV-related liver fibrosis post-successful DAA therapy. *Egypt Liver J* 2021; **11**: 56 [DOI: [10.1186/s43066-021-00129-0](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

